Novartis Vaccines Institute for Global Health (NVGH)

Partnership objectives

  1. Vaccine for Typhi and Paratyphi A.
  2. Vaccine for invasive Nontyphoidal Salmonella in Africa.
  3. Vaccine for Shigella.
  4. Vaccine for African bacterial meningitis.

New paradigms are needed for developing sustainable production of vaccines for neglected diseases. New paradigms are needed for developing sustainable production of vaccines for neglected diseases. Copyright Novartis

What are the health needs and challenges?

Infectious diseases impose the major health burden in the developing world. There is a desperate need for effective, affordable and accessible vaccines to combat these neglected infectious diseases that affect over two billion people in the developing world. Novartis is committed to improving global health and the Novartis Vaccines Institute for Global Health (NVGH) is an important part of that strategy as they discover and develop vaccines specifically addressing the needs of developing countries.

Invasive salmonella, Shigella and Meningitis are major neglected diseases of developing countries. Together these diseases are responsible for well in excess of 160 million clinical cases per year with more than 1 million deaths. These diseases predominantly infect the poorest proportion of the population and particularly impact on young children.

A major bottleneck in the path to new vaccines is the expertise and facilities needed to turn a laboratory concept into high quality vaccines that are both clinically effective and economically viable for manufacture.

Description of partnership activities and how they address needs and challenges

The Novartis Vaccines Institute for Global Health (NVGH) is a part of the Novartis Institutes for BioMedical Research that, in partnership with other organizations, aims to develop effective and affordable vaccines for neglected infectious diseases of impoverished communities. In striving to achieve this mission, NVGH aims to substantially reduce development risks and cost of new vaccines so that manufacturers will be able to viably produce and distribute these vaccines to the public health sector of the developing world. NVGH's role is to undertake the translational research required to take a laboratory concept through development to the human Proof of Concept and then to transfer this knowledge to a manufacturer.

Lessons learned                         

New paradigms are needed for developing sustainable production of vaccines for neglected diseases and this will be the subject of ongoing investigations. In 2011 there was a major effort in addressing antigenic diversity of target antigens, particularly though a new partially EU funded initiative, GENDRIVAX. This initiative involves multiple partners – demonstrating the power of combining academics and industry in the design of vaccine issues. For more on this initiative click here

Summary of impact and forward looking information

  • Clinical trial material for a vaccine against typhoid fever is in Phase 2 trials in Pakistan, India and the Philippines.
  • Laboratory proof of concept has been achieved for a vaccine against invasive Nontyphoidal salmonella for Africa.
  • Entered agreement with an Indian biopharmaceutical company (BioE) to deliver affordable vaccines against with typhoid and paratyphoid fever.

On 2 March 2015, Novartis announced the completion of a series of transactions with GlaxoSmithKline plc (GSK), including the divestiture of the Novartis non-influenza Vaccines business to GSK.

Partnership information

Company(ies) Novartis

Partner(s) Aga Khan University, Associazione Sclavo, Centre for Evaluation of Vaccine, University of Antwerp, Children’s Hospital Oakland Research Institute, Clinical Research Unit at the Hospital for Tropical Diseases, Oxford University, Coalition against Typhoid, Institute Pasteur, Kenya Medical Research Institute, King Edward Memorial Hospital, Mumbai, Malawi-Liverpool-Wellcome Trust Clinical Research Program, Oxford Vaccine Group, Research Institute for Tropical Medical, Philippines, Swiss Tropical and Public Health Institute (Swiss TPH), University of Birmingham, University of Cape Town, University of Maryland, University of Siena, University of Trieste, Wellcome Trust, Wellcome Trust Sanger Institute

Type of Partner(s) Academia / Hospitals, Multilaterals, NGOs

Therapeutic Focus Vaccine-Preventable Diseases, Women and Children's Health

Disease(s) Children's Health, Meningitis C, Paratyphoid fever, Shigella, Typhoid Fever

Program Type(s) Availability of Treatment - Technology Transfer - Scientific Collaboration and Knowledge Sharing, Prevention Programs - Vaccines, Research & Development - Development of Treatments, Research & Development - Pediatric R&D

Targeted Population(s) Children, Marginalised / Indigenous People, People with low income

Region(s) East Asia & Pacific, North America, South Asia, Sub-Saharan Africa

Number of Countries 7

Country(ies) India, Kenya, Malawi, Pakistan, Philippines, South Africa, United States of America

Start Date 2008

More information NVGH

Completed date 2015

« Typhoid and paratyphoid are major causes of life-threatening disease worldwide....This licensing deal takes us a step closer to getting much-needed affordable vaccines into the communities that need them most. »

Ted Bianco, Director of Technology Transfer and Acting Director of the Wellcome Trust